Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 59.4%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 69,800 shares, a decline of 59.4% from the March 31st total of 171,800 shares. Based on an average daily volume of 701,300 shares, the short-interest ratio is presently 0.1 days.

Astellas Pharma Trading Up 0.1 %

OTCMKTS:ALPMY opened at $9.55 on Friday. The firm has a market cap of $17.28 billion, a P/E ratio of 27.26, a PEG ratio of 1.65 and a beta of 0.32. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.31. The stock’s 50 day simple moving average is $10.53 and its 200-day simple moving average is $11.45. Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $16.91.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Thursday, April 25th. The company reported $0.11 earnings per share (EPS) for the quarter. The business had revenue of $2.79 billion for the quarter. Astellas Pharma had a return on equity of 5.85% and a net margin of 1.20%. Equities analysts anticipate that Astellas Pharma will post 0.44 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.